{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T02:18:44Z","timestamp":1793240324158,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Many cancer drugs are approved under the US Food and Drug Administration (FDA) accelerated approval pathway based on preliminary evidence. It is unclear how this limited evidence is integrated into the National Comprehensive Cancer Network (NCCN) guidelines, which are common references for clinicians and are used by public and private payers to determine reimbursement for oncology treatments.<\/jats:p><\/jats:sec>Objective<\/jats:title>To analyze the NCCN guidelines\u2019 assessments for cancer drug indications that received FDA accelerated approval compared with cancer drug indications that received FDA regular approval.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study analyzes FDA-approved indications for cancer drugs that were granted accelerated approval from program inception in 1992 to June 30, 2022. For each drug, the FDA-approved labeling was reviewed to identify all indications. All analyses were performed at the drug-indication level.<\/jats:p><\/jats:sec>Exposure<\/jats:title>The exposure was FDA regulatory status as of October 2022, including regular approval, accelerated approval, accelerated approval converted to regular approval, and withdrawn accelerated approval.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The level of evidence and consensus (category 1, 2A, 2B, and 3) and treatment preference (preferred, alternative preferred, other recommended, and useful in certain circumstances) ratings assigned by NCCN committees as of February 2023.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 315 oncology indications for 100 drugs were analyzed. These indications included 156 (50%) with regular approval, 60 (38%) with accelerated approval, 78 (49%) with accelerated approval that was converted to regular approval, and 21 (13%) with withdrawn accelerated approvals. Among all indications, 105 (33%) were rated by the NCCN as having category 1 evidence, 185 (59%) with category 2A, 6 (2%) with category 2B, and 2 (1%) with category 3 evidence. Compared with indications with regular approval, those with accelerated approval were less frequently assigned category 1 evidence (47% vs 3%; P<\/jats:italic>\u2009&amp;lt;\u2009.001) and were less often listed as preferred treatment options (58% vs 40%; P<\/jats:italic>\u2009=\u2009.008). Among the 21 withdrawn accelerated approval indications, 8 (38%) remained in the NCCN guidelines, with most having level 2A evidence ratings.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study found that cancer drug indications with accelerated approval were less likely to be assigned high-level evidence ratings and preferred status in the NCCN guidelines compared with indications with regular approval; most accelerated and regular approval drugs had low-quality evidence ratings but high levels of consensus among oncologists on NCCN committees. Greater clarity on the thresholds and definitions of evidence levels would make the NCCN guidelines more useful to clinicians, patients, and payers.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.43285","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T16:18:10Z","timestamp":1699978690000},"page":"e2343285","source":"Crossref","is-referenced-by-count":20,"title":["National Comprehensive Cancer Network Guideline Recommendations of Cancer Drugs With Accelerated Approval"],"prefix":"10.1001","volume":"6","author":[{"given":"Edward R. Scheffer","family":"Cliff","sequence":"first","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel S.","family":"Rome","sequence":"additional","affiliation":[{"name":"Palliative Medicine, Section of General Internal Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin N.","family":"Rome","sequence":"additional","affiliation":[{"name":"Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,11,14]]},"reference":[{"issue":"10","key":"zoi231252r1","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41571-018-0066-3","article-title":"Reinforcing the social compromise of accelerated approval.","volume":"15","author":"Gyawali","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"zoi231252r2","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamainternmed.2019.0462","article-title":"Assessment of the clinical benefit of cancer drugs receiving accelerated approval.","volume":"179","author":"Gyawali","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi231252r3","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review.","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"issue":"3","key":"zoi231252r4","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2023.0217","article-title":"Timing of confirmatory trials for drugs granted accelerated approval based on surrogate measures from 2012 to 2021.","volume":"4","author":"Deshmukh","year":"2023","journal-title":"JAMA Health Forum"},{"issue":"9","key":"zoi231252r5","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jama.2023.0625","article-title":"Association between preapproval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway.","volume":"329","author":"Shahzad","year":"2023","journal-title":"JAMA"},{"issue":"21","key":"zoi231252r6","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMp1700446","article-title":"Accelerated approval and expensive drugs - a challenging combination.","volume":"376","author":"Gellad","year":"2017","journal-title":"N Engl J Med"},{"key":"zoi231252r7","doi-asserted-by":"publisher","first-page":"n1959","DOI":"10.1136\/bmj.n1959","article-title":"Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study.","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"},{"issue":"24","key":"zoi231252r8","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1001\/jama.2022.22986","article-title":"The FDA struggle to withdraw Makena: problems with the accelerated approval process.","volume":"328","author":"Aaron","year":"2022","journal-title":"JAMA"},{"issue":"14","key":"zoi231252r9","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMp2116863","article-title":"The Wild West of checkpoint inhibitor development.","volume":"386","author":"Beaver","year":"2022","journal-title":"N Engl J Med"},{"issue":"18","key":"zoi231252r10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2104846","article-title":"\u201cDangling\u201d accelerated approvals in oncology.","volume":"384","author":"Beaver","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi231252r11","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.1200\/JCO.23.00225","article-title":"Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival.","volume":"41","author":"Merino","year":"2023","journal-title":"J Clin Oncol"},{"key":"zoi231252r12","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100332","article-title":"Evaluating the evidence behind the surrogate measures included in the FDA\u2019s table of surrogate endpoints as supporting approval of cancer drugs.","volume":"21","author":"Gyawali","year":"2020","journal-title":"EClinicalMedicine"},{"issue":"16","key":"zoi231252r13","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1056\/NEJMp2208954","article-title":"The on- and off-ramps of oncology accelerated approval.","volume":"387","author":"Fashoyin-Aje","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi231252r14","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1001\/jamaoncol.2021.3046","article-title":"The Oncologic Drugs Advisory Committee votes of April 2021-implications for the fate of accelerated approval.","volume":"7","author":"Powell","year":"2021","journal-title":"JAMA Oncol"},{"issue":"12","key":"zoi231252r15","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41408-017-0008-9","article-title":"Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals.","volume":"7","author":"Lammers","year":"2017","journal-title":"Blood Cancer J"},{"issue":"9","key":"zoi231252r16","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1200\/JCO.2012.42.7252","article-title":"Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists.","volume":"31","author":"Conti","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"zoi231252r17","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1001\/jama.2016.12770","article-title":"Time to reassess the cancer compendia for off-label drug coverage in oncology.","volume":"316","author":"Green","year":"2016","journal-title":"JAMA"},{"key":"zoi231252r18","doi-asserted-by":"publisher","first-page":"k668","DOI":"10.1136\/bmj.k668","article-title":"Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.","volume":"360","author":"Wagner","year":"2018","journal-title":"BMJ"},{"issue":"3","key":"zoi231252r19","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.0841","article-title":"Changes in length and complexity of clinical practice guidelines in oncology, 1996-2019.","volume":"3","author":"Kann","year":"2020","journal-title":"JAMA Netw Open"},{"key":"zoi231252r23","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00821-7","article-title":"Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma.","author":"Cliff","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"12","key":"zoi231252r27","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","article-title":"Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals.","volume":"175","author":"Kim","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"2","key":"zoi231252r28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters.","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"issue":"9","key":"zoi231252r29","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.6004\/jnccn.2020.7690","article-title":"Underperformance of contemporary phase III oncology trials and strategies for improvement.","volume":"19","author":"Shen","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"zoi231252r30","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1001\/jamaoncol.2016.2710","article-title":"Financial relationships with industry among National Comprehensive Cancer Network guideline authors.","volume":"2","author":"Mitchell","year":"2016","journal-title":"JAMA Oncol"},{"issue":"16","key":"zoi231252r31","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1002\/cncr.v126.16","article-title":"Financial conflicts of interest among National Comprehensive Cancer Network clinical practice guideline panelists in 2019.","volume":"126","author":"Desai","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"zoi231252r32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.2010.31.6414","article-title":"Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines.","volume":"29","author":"Poonacha","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi231252r33","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1002\/hec.v27.1","article-title":"State insurance mandates and off-label use of chemotherapy.","volume":"27","author":"Smieliauskas","year":"2018","journal-title":"Health Econ"},{"issue":"12","key":"zoi231252r35","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1377\/hlthaff.2021.00762","article-title":"Raising Medicaid rebates for drugs with accelerated approval.","volume":"40","author":"Rome","year":"2021","journal-title":"Health Aff (Millwood)"},{"key":"zoi231252r20","unstructured":"Zynlonta: loncastuximab tesirine for healthcare professionals. ADC Therapeutics. August 2023. Accessed May 7, 2023. https:\/\/www.zynlontahcp.com\/"},{"key":"zoi231252r21","unstructured":"FDA approves Genentech\u2019s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma. Genentech. April 19, 2023. Accessed May 7, 2023. https:\/\/www.gene.com\/media\/press-releases\/14988\/2023-04-19\/fda-approves-genentechs-polivy-in-combin"},{"key":"zoi231252r22","unstructured":"Venclexta: healthcare providers. AbbVie. Accessed September 2, 2023. https:\/\/www.venclextahcp.com\/"},{"key":"zoi231252r24","unstructured":"Cancer accelerated approvals. US Food and Drug Administration. September 8, 2023. Accessed May 4, 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/ongoing-cancer-accelerated-approvals"},{"key":"zoi231252r25","unstructured":"NCCN clinical practice guidelines in oncology: treatment by cancer type. National Comprehensive Cancer Network. Updated October 19, 2022. Accessed October 25, 2023. https:\/\/www.nccn.org\/guidelines\/category_1"},{"key":"zoi231252r26","unstructured":"Development and update of guidelines. National Comprehensive Cancer Network. 2023. Accessed May 7, 2023. https:\/\/www.nccn.org\/guidelines\/guidelines-process\/development-and-update-of-guidelines"},{"key":"zoi231252r34","unstructured":"HHS secretary responds to the President\u2019s executive order on drug prices. Centers for Medicare & Medicaid Services. February 14, 2023. Accessed May 7, 2023. https:\/\/www.cms.gov\/newsroom\/press-releases\/hhs-secretary-responds-presidents-executive-order-drug-prices"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2811820\/cliff_2023_oi_231252_1699303121.54522.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T16:18:15Z","timestamp":1699978695000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2811820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,14]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.43285","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,14]]}}}